Gruca, Martin M. http://orcid.org/0000-0002-2705-4821
Li, Yun
Kong, Xiaowen
DeCamillo, Deborah
Kline-Rogers, Eva
Ali, Mona A.
Kaatz, Scott
Dahu, Musa
Froehlich, James B.
Barnes, Geoffrey D.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K01HL135392)
Blue Cross Blue Shield of Michigan Foundation
Article History
First Online: 20 May 2019
Compliance with ethical standards
:
: Dr. Barnes reports grants from Pfizer/Bristol-Myers-Squib, Blue Cross Blue Shield of Michigan, National Heart Lung and Blood Institute during the conduct of the study. Dr. Barnes reports consulting fees from Pfizer/Bristol-Myers-Squib, Janssen, and Portola outside of the submitted work. Dr. Froehlich reports grant support from Blue Cross/Blue Shield of Michigan and the Fibromuscular Disease Society of America. Dr. Froehlich reports consulting fees for Merck, Janssen, and Novartis outside of the submitted work. Dr. Froehlich serves on the Advisory Committee of Boehringer-Ingelheim and Pfizer. Dr. Kaatz reports grants from Blue Cross Blue Shield of Michigan and Janssen during the conduct of the study. Dr. Kaatz reports consulting fees from Pfizer, Bristol Myer Squibb, Daiichi Sankyo, Portola, Roche, and Boehringer Ingelheim outside of the submitted work. Ms. Kline-Rogers reports consulting fees from Anticoagulation Forum and Janssen Pharmaceuticals outside of the submitted work. All other authors have no disclosures.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Given the retrospective nature of this study and the minimal risk that it presented to subjects, this study was granted a waiver of informed consent from our respective Institutional Review Board.